Which statement best describes when to consider therapeutic drug monitoring for a new drug with unpredictable pharmacokinetics?

Which statement best describes when to consider therapeutic drug monitoring for a new drug with unpredictable pharmacokinetics?

• A. Only if the drug has a wide therapeutic index
• B. Only if the pharmacokinetics are predictable
• C. All of the above factors are irrelevant to TDM decisions
• D. All of the above should be considered

Answer: (D)

Therapeutic drug monitoring is most useful when you’re dealing with variables that can change a patient’s drug exposure and response. For a new drug with unpredictable pharmacokinetics, you don’t want to rely on a single rule; you assess multiple factors that influence how much drug is in the body and how safely it can be used. The therapeutic window matters: drugs with a narrow window require closer monitoring because small changes in exposure can push you from subtherapeutic to toxic. But unpredictable PK means exposure can vary between patients even at the same dose, so you should consider TDM as part of a broader evaluation of whether monitoring will improve safety and efficacy. Saying you should monitor only if the therapeutic index is wide isn’t right, because a wide window actually reduces the need for TDM rather than creates a demand for it. Saying you should monitor only if PK are predictable is also off, since predictable PK reduces the need for TDM, whereas unpredictable PK is what pushes you toward it. Treating all factors as irrelevant is clearly wrong. The best approach is to consider all relevant factors that could affect drug exposure and response, so deciding on TDM in this context is a comprehensive, case-by-case choice.

Therapeutic drug monitoring is most useful when you’re dealing with variables that can change a patient’s drug exposure and response. For a new drug with unpredictable pharmacokinetics, you don’t want to rely on a single rule; you assess multiple factors that influence how much drug is in the body and how safely it can be used. The therapeutic window matters: drugs with a narrow window require closer monitoring because small changes in exposure can push you from subtherapeutic to toxic. But unpredictable PK means exposure can vary between patients even at the same dose, so you should consider TDM as part of a broader evaluation of whether monitoring will improve safety and efficacy. Saying you should monitor only if the therapeutic index is wide isn’t right, because a wide window actually reduces the need for TDM rather than creates a demand for it. Saying you should monitor only if PK are predictable is also off, since predictable PK reduces the need for TDM, whereas unpredictable PK is what pushes you toward it. Treating all factors as irrelevant is clearly wrong. The best approach is to consider all relevant factors that could affect drug exposure and response, so deciding on TDM in this context is a comprehensive, case-by-case choice.